Investigational drug · Phase 2
ONO-1110
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Fibromyalgia, Social Anxiety Disorder (SAD), Major Depressive Disorder (MDD.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
5
0 still active
All registered trials
5
Any phase or sponsor naming "ONO-1110"
First trial start
2025
Jan 16, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ONO-1110", any sponsor or status.
Conditions studied
As listed on its trial records.
- Fibromyalgia
- Social Anxiety Disorder (SAD)
- Major Depressive Disorder (MDD
- Hunner Type Interstitial Cystitis
- Postherpetic Neuralgia
Approved drugs for the same conditions: Neuropathic pain · Depression (major depressive disorder) · Anxiety disorders · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "ONO-1110" as an intervention, largest first.
- A Clinical Study of ONO-1110 in Patients With FibromyalgiaPivotal-lookingCompleted
Ono Pharmaceutical Co., Ltd.Industry
NCT06752590 · 175 participants · Start Mar 26, 2025 · Primary completion May 30, 2026
Drug: ONO-1110; Placebo · For: Fibromyalgia
Sites: Nagakute, Japan; Nagoya, Japan; Yotsukaidō, Japan · 30 sites in all
- A Study of ONO-1110 in Patients With Postherpetic NeuralgiaPivotal-lookingCompleted
Ono Pharmaceutical Co., Ltd.Industry
NCT06708416 · 142 participants · Start Feb 12, 2025 · Primary completion May 11, 2026
Drug: ONO-1110; Placebo · For: Postherpetic Neuralgia
Sites: Aichi, Japan; Fukuoka, Japan; Fukushima, Japan · 31 sites in all
- A Study of ONO-1110 in Patients With Social Anxiety DisorderPivotal-lookingCompleted
Ono Pharmaceutical Co., Ltd.Industry
NCT06805565 · 115 participants · Start Jan 31, 2025 · Primary completion May 25, 2026
Drug: ONO-1110; Placebo · For: Social Anxiety Disorder (SAD)
Sites: Fukuoka, Japan; Gunma, Japan; Hokkaido, Japan · 27 sites in all
- A Study of ONO-1110 in Patients With Major Depressive DisorderPivotal-lookingCompleted
Ono Pharmaceutical Co., Ltd.Industry
NCT06792136 · 103 participants · Start Jan 16, 2025 · Primary completion Apr 9, 2026
Drug: ONO-1110; Placebo · For: Major Depressive Disorder (MDD
Sites: Fukuoka, Japan; Gunma, Japan; Hokkaido, Japan · 29 sites in all
Ono Pharmaceutical Co., Ltd.Industry
NCT06752603 · 57 participants · Start Apr 2, 2025 · Primary completion Jun 12, 2026
Drug: ONO-1110; Placebo · For: Hunner Type Interstitial Cystitis
Sites: Nagoya, Japan; Fukuoka, Japan; Fukushima, Japan · 20 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Fibromyalgia
- AXS-14EsreboxetinePhase 32 trials
Axsome Therapeutics, Inc. · Fibromyalgia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.